Pilar Giraldo – Medical field – Lifetime achievement Award

Published on by Network Science

Pilar Giraldo – Medical field – Lifetime achievement Award

Dr. Pilar Giraldo distinguished academic and researcher in the field Identification of patient-reported outcome measures and patient-reported experience measures in Gaucher disease in Spain. Dr. Pilar Giraldo Castellano appears highly suitable for the Research for Lifetime Achievement Award based on her extensive contributions and accomplishments in the field of hematology, particularly focusing on rare diseases.

🌐 Professional Profile

Educations📚📚📚

  • PhD in Medicine and accredited as a Full Professor by ANECA.
  • Master’s in Research Methodology and Molecular Oncology.
  • Coordinator of Doctorate studies at University San Jorge.

  • Research and Publications:

    • Head of research group Unit 752 of the Center for Biomedical Research Network on Rare Diseases (CIBERER).
    • Published over 140 articles in peer-reviewed journals, more than 20 book chapters, and 5 monographs.
    • Holds 5 patents related to her field.

  • Leadership in Research Projects:

    • Principal Investigator in numerous significant projects, such as the National Plan project TED2021-131518B-C32.
    • Directed more than 20 doctoral theses.
    • Led various research initiatives focusing on lysosomal diseases and other hematological conditions.

  • International Recognition and Collaboration:

    • Organized national and international congresses, including the 12th EWGGD Congress in 2016.
    • Part of the Expert Committee of the IWGGD and the Task Force on GD of the EHA.
    • Collaborates extensively with international bodies and foundations.

  • Awards and Recognition:

    • Received multiple awards for her contributions and those of her research group members at national and international congresses.
    • Recognized for her innovative work in utilizing artificial intelligence and machine learning in medical research.

  • Teaching and Mentorship:

    • Directed numerous continuing education courses for physicians.

Created educational resources and has been involved in life-long learning activities.

📝🔬Publications📝🔬

  • Elstein D, Belmatoug N, Bembi B, Deegan P, Fernandez-Sasso D, Giraldo P,
    Göker-Alpan Ö, Hughes D, Lau H, Lukina E, Revel-Vilk S, Schwartz IVD, Istaiti M, Botha J,
    Gadir N, Schenk J, Zimran A; GOS Study Group. 2024. Twelve Years of the Gaucher
    Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global
    Patient Registry.J Clin Med.13-12.
  • Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart
    A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta
    A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V,
    Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, BrillAlmon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG.;. 2024. Head-to-head trial
    of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and
    deteriorating renal function: results from the 2-year randomised phase III BALANCE
    study. J Med Genet.21-61, pp.520-530.
  • Serrano-Gonzalo I, de Frutos LL, Lahoz-Gil C, Delgado-Mateos F, FernándezGalán MÁ, Morales-Conejo M, Calle-Gordo MV, Ibarretxe-Gerediaga D, MadinaveitiaOchoa A, Albarracin-Arraigosa A, Balanzat-Muñoz J, Correcher-Medina P, García-Frade LJ,
    Hernández-Rivas JM, Labbadia F, López-Dupla JM, Lozano-Almela ML, Mora-Casterá E,
    Noya-Pereira MS, Ruíz-Guinaldo MÁ, Del Mar Tormo-Díaz M, Vitoria-Miñana I, ArévaloVargas I, Andrade-Campos M, Giraldo P. Real life data: follow-up assessment on Spanish
    3
    Gaucher disease patients treated with eliglustat. TRAZELGA project.. 2023. Real life data:
    follow-up assessment on Spanish Gaucher disease patients treated with eliglustat.
    TRAZELGA project. Orphanet J Rare Dis.18-1.
  • Stanescu S, Correcher Medina P, Del Castillo FJ, Alonso Luengo O, Arto
    Millan LM, Belanger Quintana A, Camprodon Gomez M, Diez Langhetée L, Garcia Campos
    O, Matas Garcia A, Perez-Moreno J, Rubio Gribble B, Visa-Reñé N, Giraldo-Castellano P,
    O’Callaghan Gordo M. 2023. Clinical Outcomes of Patients with Chronic Neuropathic
    Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective
    Study.Biomedicines.11-10.
  • Linhart A, Dostálová G, Nicholls K, West ML, Tøndel C, Jovanovic A, Giraldo P,
    Vujkovac B, Geberhiwot T, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Hughes. 2023.
    Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were
    previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
    Orphanet J Rare Dis. 18-1, pp.332.
  • Louw VJ, Fraser I, Giraldo P 2023. Management goals of type 1 Gaucher
    disease in South Africa: An expert Delphi consensus document on good clinical
    practice.PLoS One. 18-8.
  • Esther Valero Tena; Mercedes Roca Espiau; Jose Verdu Diaz; Jordi Diaz
    Manera; Marcio Andrade Campos; Pilar Giraldo Castellano. 2023. Advantages of digital
    technology in the assessment of bone marrow involvement in Gaucher’s disease. Front Med
    (Lausanne).

Miguel Angel Rodríguez Cabello -Medicine and Health Sciences – Best Researcher Award

Published on by Network Science

Miguel Angel Rodríguez Cabello -Medicine and Health Sciences – Best Researcher Award

Dr. Miguel Angel Rodríguez Cabello distinguished academic and researcher in the field Medicine and Health Sciences. He completed several postgraduate programmes at CEU and Cardenal Herrera University from October 2018 to July 2019, including expertise in Medical Direction and Health Services Management, Medical Direction and Management of Clinical Units, Quality Medical Management, and Leadership and Directing Skills in Health. Additionally, he earned a Certificate of Da Vinci System Training as a Console Surgeon on 16th October 2017, at EU Direct: IRCAD in Strasbourg, France. Currently, he is pursuing a Master’s Degree in Clinical, Medical, and Assistance Management at CEU and Cardenal Herrera University. He participated in the Salzburg ESU Weill Cornell Seminar in Masterclass in Urology in Salzburg, Austria, from 9th to 15th July 2017, earning 37 DFP credits from the Austrian Chamber of Physicians. He is a member of EU-ACME, the European Board of Urology (EBU), and the European Association of Urology (EAU).

He completed a hands-on training course on Laparoscopy and Endourology, accredited by the European Accreditation Council for Continuing Medical Education, earning 24 European CME credits from 31st January to 3rd February 2017 in Cáceres, Spain. He also participated in the European Training in Basic Laparoscopic Urological Skills (E-BLUS) on 13th March 2016 at the 31st Annual Congress of the European Association of Urology in Munich, Germany, under Dr. J. Palou. He became a Fellow of the European Board of Urology (F.E.B.U.) after passing the EBU Written Examination on 14th November 2014 with a qualification of 8, and the EBU Oral Examination on 6th June 2015 in Brussels, Belgium, with a successful qualification of 7/9.

He completed a postgraduate programme on expertise in Urological Ultrasound at the University of Zaragoza during the VI Course 2015–2016. He holds a Diploma in Design and Statistics and a Master’s Degree in Research Methodology from Universidad Autónoma de Barcelona (Spain). Additionally, he completed a postgraduate programme on expertise in Statistics Applied to Health Sciences at UNED during the 2012-2013 academic year, earning an outstanding qualification and 20 ECTS credits (500 hours).

🌐 Professional Profile

Educations📚📚📚

He holds a PhD in Medicine and Surgery from Universidad Autónoma de Madrid, awarded on 9th June 2023, with his thesis receiving an Outstanding qualification with Cum Laude mention by unanimity. He also earned two Postgraduate Diplomas in 2023 from Universidad Autónoma de Barcelona: one in Systematic Review of Studies: Meta-Analysis and Evaluation Tests, and another in Systematic Review of Studies: Synthesis of Information. In March 2023, he completed the Aquablation Therapy Training Programme, receiving a Certificate of Completion from Procept BioRobotics. He holds a Master’s Degree in Research Methodology: Design and Statistics in Health Sciences from Universidad Autónoma de Barcelona, which he completed between 2017 and 2021. Additionally, he completed the Rezūm Procedure Healthcare Practitioner Training in August 2020, acknowledged by Boston Scientific. His academic achievements also include a Diploma in Design and Statistics and a Master in Research Methodology from Universidad Autónoma de Barcelona, obtained between 2016 and 2020. Furthermore, he holds a Master’s Degree in Clinical, Medical, and Care Management.

 

Work Experience

He has been working as a Physician Specialist in Urology at University Hospital La Moraleja in Madrid since May 2015 and as a Physician Specialist in Urology and Infertility at OVOCLINIC in Madrid since September 2021. Previously, he was a resident at the Urology Department of University Hospital Ramón y Cajal in Madrid, Spain, from May 2010 to May 2015, and worked as a General Physician at Company Medycsa, Calle Valentín Beato 5, Madrid, between 2009 and 2010. He completed a Fellowship in Laparoscopic and Robotic Urological Surgery at Saint Augustin Clinic, Bordeaux (France) from September to November 2014 and participated in the Salzburg ESU Weill Cornell Seminar in Masterclass in Urology, organised by the European Association of Urology, European School of Urology (ESU), and Weill Cornell Medicine, earning 37 DFP credits from the Austrian Chamber of Physicians in Salzburg, Austria, from 9th to 15th July 2017. From 2010 to 2014, he was a Professor of Urology at CTO Medicina, delivering 180 hours of lectures under the direction of Dr. Roberto Garcia Leal. He supervised residents during their incorporation into the Department of Urology and provided education and oversight to students of the Medicine Degree at Universidad Francisco de Vitoria as well as to residents of Gynecology.

From 2020 to 9th June 2023, he was a Ph.D. student in Medicine and Surgery at Universidad Autónoma de Madrid, where he studied the diagnostic validity of predictive models in prostate cancer using the Prostate Imaging and Data Reporting System version 2 (PIRADSv2) and PSA density. Since 2023, he has been the principal investigator of a randomised, double-blind, placebo-controlled study evaluating the effect of a probiotic on urinary tract microbiota in women with recurrent urinary tract infections (rUTI), study code IC-HULM-007-23, known as the PROBUTI study. Since 2021, he has been an independent technical evaluator of research projects, R+D+I, and technological innovation. He is currently the principal investigator in the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study at University College London (UCL), which assesses whether bi-parametric MRI is non-inferior to multi-parametric MRI in diagnosing clinically significant prostate cancer. Additionally, he actively collaborates as the principal investigator in the phase 3 clinical trial E.mbrace Amendment 2 VAC52416 (JNJ-78901563 [ExPEC9V]), a study aimed at assessing the efficacy, safety, and immunogenicity of vaccination with ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.

His ongoing research projects include a comparative study between multiparametric magnetic resonance systems of 1.5 and 3 Teslas using the PIRADS version 2 classification in the diagnosis of prostate cancer (registered under number 40/2021); a cross-sectional study of PSA density assessment and multiparametric resonance as predictors of prostate cancer (registered under number 39/2021); and the evaluation of the Oncotype Dx genetic test in therapeutic decisions for low-risk prostate cancer, a multicenter study (registered under number 29/2021). From 2020 to the present, he has been conducting research on predictive models and validation of diagnostic tests in prostate cancer, focusing on multiparametric prostate MRI and fusion prostate biopsy as part of his PhD at Universidad Autónoma de Madrid. Between 2018 and 2019, he actively collaborated in the RITUMAN study, a multicenter and coordinated study on the management of patients with recurrent urinary tract infections. From 2016 to 2017, he contributed to the PREVENT-LIT study, which focused on the management of patients with urolithiasis. From 2011 to 2013, he participated in the EMPARO-CU study, a multicenter and coordinated study examining the care process and outcomes in a cohort of patients diagnosed with urological cancer (bladder and prostate).

 

📝🔬Publications📝🔬
  • Giganti F, Ng A, Asif A, Chan VW, Rossiter M, Nathan A, Khetrapal P, Dickinson L,
    Punwani S, Brew-Graves C, Freeman A, Emberton M, Moore CM, Allen C,
    Kasivisvanathan V; PRIME Quality Improvement Group. Global Variation in Magnetic
    Resonance Imaging Quality of the Prostate. Radiology. 2023 Oct;309(1):e231130. doi:
    10.1148/radiol.231130. PMID: 37815448. Contributor.
  • Miguel Angel Rodríguez Cabello, Santiago Méndez Rubio, Juan Luis Sanz Miguelañez,
    Alvaro Moraga Sanz, Carolina Aulló González, Arturo Platas Sancho. Prevalence and
    grade of malignancy differences with respect to the area of involvement in
    Curriculum Vitae
    Miguel Ángel Rodríguez Cabello
    5
    multiparametric resonance imaging of the prostate in the diagnosis of prostate
    cancer using the PI-RADS version 2 classification. World J Urol. 2023 May 30. DOI:
    10.1007/s00345-023-04466-0.
  • Cabello, R., Mendez Rubio, S., Sanz Miguelanez, J. L., Vazquez Alba, D., Moraga Sanz, A.,
    & Platas Sancho, A. (2023, February). The importance of the location of the PI-RADS
    lesion within the prostate as a predictive variable of malignant degree. In EUROPEAN
    UROLOGY (Vol. 83, pp. S432-S432). RADARWEG 29, 1043 NX AMSTERDAM,
    NETHERLANDS: ELSEVIER.
  • Rodríguez Cabello MA, Méndez Rubio S, Platas Sancho A, Carballido Rodríguez J.
    Diagnostic evaluation and incorporation of PSA density and the prostate imaging
    and data reporting system (PIRADS) version 2 classification in risk-nomograms for
    prostate cancer. World J Urol. 2022 Oct;40(10):2439-2450. doi: 10.1007/s00345-022-
    04118-9. Epub 2022 Aug 8. PMID: 35941245.
  • Rodríguez Cabello, M.A., Méndez Rubio, S., Moraga Sanz, A., Sanz Miguelañez, J.L.,
    Vázquez Alba, D., Aulló González, C., Platas Sancho, A. Comparative study between
    1.5 and 3 Tesla multiparametric magnetic resonance imaging systems using the
    PIRADS version 2 classification in the diagnosis of prostate cancer. Arch-Esp-Urol
    2022;75(4):330–8.
  • Garrido-Abad P, Rodriguez-Cabello MÁ, Platas-Sancho A. Steinstrasse following
    extracorporeal shock wave lithotripsy. Arch Esp Urol. abril de 2021;74(3):363-4.
    PMID: 33818435.